| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Salubrinal | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |